Thermo Fisher stock was a new position in Edgewood Management’s Large Cap Growth Equity portfolio in the third quarter of 2026, as demand from drug developers and biotechnology companies recovered.

Why Edgewood added Thermo Fisher stock

Edgewood identified Thermo Fisher Scientific as a new holding in its third-quarter fund letter and highlighted the company’s market position and recovering customer demand.

The available information does not specify the size of the position or when during the quarter it was established.

Third-quarter company results

Thermo Fisher’s third-quarter results, released on October 21, showed revenue of $12.14 billion, up 9% from a year earlier. Organic revenue grew 6%. The quarter ended September 26.

GAAP diluted earnings per share rose 9% to $4.64, while adjusted earnings per share increased 15% to $6.68. Adjusted earnings are a non-GAAP measure that excludes certain items.

Read More News

More FinanceVelix news

Disclaimer

This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.